Discuss the merits and risks of a fund-of-funds model, using Second Level Fund Managers, for financing deep-tech R&D in India.

India's GERD is only 0.64% of GDP, and private firms contribute just 36% of it [6]. The ₹1 lakh crore RDI Fund addresses this through a two-tier fund-of-funds. A Special Purpose Fund within ANRF holds the corpus and channels it through Second Level Fund Managers (SLFMs), such as AIFs, DFIs, NBFCs and FROs, to deep-tech firms [2][3]. The design has real strengths but also clear risks.

Merits

• Leverage: each SLFM must raise private capital equal to the RDIF contribution. The first cohort of 19 SLFMs (14 AIFs and 5 FROs) received ₹7,131 crore, which could therefore mobilise roughly double that amount [1].
• Professional selection: the state avoids picking individual firms. Managers are screened by an Expert Advisory Committee, the ANRF Executive Council and the EGoS [1].
• Patient, recyclable capital: support comes as long-term low-interest loans and equity, not grants, so repayments return to the corpus [4].
• Bridges the "valley of death": it funds firms at TRL 4 and above. This stage is too late for most grants and too risky for collateral-based bank lending [1].
• Diverse channels: mission-driven FROs work alongside VC-style AIFs, while TDB and BIRAC serve sectoral niches [1][5].

Risks

• Principal-agent problem: managers may chase safe, quick returns instead of strategic but risky technologies. Management fees also reduce the money that reaches firms.
• Commitment is not disbursement: money flows only as SLFMs find projects. Even total commitments, including ₹1,000 crore each to TDB and BIRAC, are still under a tenth of the corpus [1][5].
• Concentration: 200 applicants sought about ₹8,000 crore, but only 19 were approved [5][1]. This favours large managers.
• Thin pipeline: India has about 260 researchers per million people, against 1,602 in China. This limits the number of bankable TRL 4+ projects [6].
• Deadweight and neglect of basic research: cheap loans may fund R&D that firms would do anyway, while TRL 1–3 research gets no support [1].
• Slow approvals: the first cohort was approved over eight months after applications closed in January 2026 [3][1].

The fund-of-funds model turns a fiscal corpus into leveraged, market-disciplined patient capital, which is a sound bet for deep-tech. Its success depends on three things. Each SLFM's disbursements and private capital raised should be published. Manager reviews should be tied to whether funded R&D is genuinely additional. ANRF grants should be protected so that they keep feeding the TRL 4 pipeline. With these safeguards, the RDIF can move India towards its 2% of GDP GERD goal [6] and support Atmanirbhar Bharat [1].